Cytogenetic characteristics predict outcome of patients with poor risk MDS and secondary AML (sAML) treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukaemia Groups

被引：0
|
作者：
de Witte, T
Hagemeijer, A
Suciu, S
Delforge, M
Jotterand-Bellomo, M
Tigaud, I
Belhabri, A
Aul, C
Avaido, M
Selleslag, D
Schouten, H
Ferrant, A
Amadori, S
Muus, P
Anak, O
Beeldens, F
Jansen, J
Hellstrom-Lindberg, E
Gratwohl, A
Willemze, R
机构：
来源：
BONE MARROW TRANSPLANTATION | 2002年 / 29卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
O323
引用
收藏
页码：S55 / S55
页数：1
相关论文
共 22 条
  • [1] Cytogenetic risk group and cytogenetic response predict outcome of patients with poor-risk MDS and secondary AML treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups.
    de Witte, T
    Hagemeijer, A
    Suciu, S
    Delforge, M
    Jotterand-Bellomo, M
    Tigaud, I
    Belhabri, A
    Aul, C
    Avaido, M
    Schouten, H
    Ferrant, A
    Amadori, S
    Muus, P
    Anak, O
    Beeldens, F
    Jansen, J
    Hellstrom-Lindberg, E
    Gratwohl, A
    Willemze, R
    BLOOD, 2001, 98 (11) : 619A - 620A
  • [2] Autologous stem cell transplantation for patients with poor risk MDS and secondary AML (sAML). A joint study of the EORTC, EBMT, SAKK and GIMEMA leukemia groups.
    DeWitte, T
    Suciu, S
    Verhoef, G
    Labar, B
    Archimbaud, E
    Aul, C
    Selleslag, D
    Ferrant, A
    Wijermans, P
    Mandelli, F
    Amadori, S
    Jehn, U
    Muus, P
    DeMuynck, H
    Dardenne, M
    Zittoun, R
    Willemze, R
    Gratwohl, A
    Apperley, J
    BLOOD, 1997, 90 (10) : 2594 - 2594
  • [3] The impact of cytogenetic features and clonality on the prognosis of patients with poor-risk MDS and secondary AML treated with intensive chemotherapy and stem cell transplantation:: A joint study of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups.
    de Witte, T
    Suciu, S
    van Dijk, J
    Delforge, M
    Hagemeijer, A
    Jotterand-Bellomo, M
    Tigaud, I
    Belhabri, A
    Aul, C
    Avaido, M
    Selleslag, D
    Schouten, H
    Ferrant, A
    Amadori, S
    Muus, P
    Anak, Ö
    Gratwohl, A
    Willemze, R
    BLOOD, 2000, 96 (11) : 546A - +
  • [4] The impact of post-remission therapy on outcome of patients with poor-risk AIDS and secondary AML treated with intensive chemotherapy with or without stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAK, HOVON, Scandinavian, and the Gimema leukemia groups.
    De Witte, TM
    Hagemeijer, A
    Suciu, S
    Belhabri, A
    Delforge, M
    Aul, C
    Avaido, M
    Selleslag, D
    Schouten, H
    Biersack, H
    Ferrant, A
    Kovacsovics, T
    Muus, P
    Jansen, J
    Beeldens, F
    Gratwohl, A
    Hess, U
    Helström-Lindberg, E
    Wijermans, P
    Ossenkoppele, G
    Marie, JP
    Willemze, R
    Amadori, S
    BLOOD, 2003, 102 (11) : 185A - 185A
  • [5] The prognostic impact of cytogenetic features and clonality of patients with poor risk MDS and secondary AML (sAML) after treatment with intensive chemotherapy and stem cell transplantation for the treatment; a joint study of the EORTC, EBMT, SAK, HOVO
    de Witte, T
    Suciu, S
    Delforge, M
    Hagemeijer, A
    Jotterrand-Bellomo, M
    Tigaud, I
    Belhabi, A
    Aul, C
    Avaido, M
    Selleslag, D
    Schouten, H
    Ferrant, A
    Amadori, S
    Muus, P
    Anak, O
    Gratwohl, A
    Willemze, R
    van Dijk, J
    BONE MARROW TRANSPLANTATION, 2001, 27 : S255 - S255
  • [6] The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921)
    M Oosterveld
    S Suciu
    G Verhoef
    B Labar
    A Belhabri
    C Aul
    D Selleslag
    A Ferrant
    P Wijermans
    F Mandelli
    S Amadori
    U Jehn
    P Muus
    R Zittoun
    U Hess
    Ö Anak
    F Beeldens
    R Willemze
    T de Witte
    Leukemia, 2003, 17 : 859 - 868
  • [7] The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation:: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921)
    Oosterveld, M
    Suciu, S
    Verhoef, G
    Labar, B
    Belhabri, A
    Aul, C
    Selleslag, D
    Ferrant, A
    Wijermans, P
    Mandelli, F
    Amadori, S
    Jehn, U
    Muus, P
    Zittoun, R
    Hess, U
    Anak, Ö
    Beeldens, F
    Willemze, R
    de Witte, T
    LEUKEMIA, 2003, 17 (05) : 859 - 868
  • [8] The impact of post-remission therapy on outcome of patients with poor risk MDS and secondary AML (sAML) treated with intensive chemotherapy with or without stem cell transplantation in a joint study
    de Witte, T
    Hagemeijer, A
    Suciu, S
    Belhabri, A
    Delforge, M
    Aul, C
    Aivado, M
    Selleslag, D
    Schouten, H
    Runde, V
    Ferrant, A
    Kovacsovics, T
    Muus, P
    Jansen, J
    Beeldens, F
    Gratwohl, A
    Hess, U
    Helström-Lindberg, E
    Wijermans, P
    Ossenkoppele, G
    Marie, JP
    Willemze, R
    Amadori, S
    BONE MARROW TRANSPLANTATION, 2004, 33 : S2 - S2
  • [9] Intensive chemotherapy followed by stem cell transplantation for patients with poor-risk mds and secondary AML (sAML).
    De Witte, T
    Suciu, S
    Verhoef, G
    Labar, B
    Archimbaud, E
    Aul, C
    Selleslag, D
    Ferrant, A
    Wijermans, P
    Mandelli, F
    Amadori, S
    Jehn, U
    Muus, P
    DeMuynck, H
    Dardenne, M
    Zittoun, R
    Willemze, R
    Gratwohl, A
    Apperley, J
    BLOOD, 1998, 92 (10) : 714A - 714A
  • [10] The impact of the presence of an HLA-identical donor on the prognosis of patients with high risk MDS and AML following MDS treated with an intensive antileukemic therapy: A joint study of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups.
    Oosterveld, M
    de Witte, T
    Suciu, S
    Verhoef, G
    Labar, B
    Belhabri, A
    Schouten, H
    Aul, C
    Runde, V
    Ferrant, A
    Selleslag, D
    Amadori, S
    Jehn, U
    Muus, P
    Anak, O
    Marie, JP
    Willemze, R
    Gratwohl, A
    Niederwieser, D
    BLOOD, 2000, 96 (11) : 357B - 357B
123